HERANTIS PHARMA

Toward clinical breakthroughs based on leading science

Aktiespararna, Stockholm 10th Sep 2019 Pekka Simula, CEO

Disclaimer

- This presentation does not intend to provide a thorough and detailed view of Herantis Pharma Plc ('Company'). The information provided in this presentation shall not be considered sufficient for making any investment decisions related to the Company. Anyone considering an investment in the Company shall read and consider carefully all information provided in the formal prospectus approved by Finland's Financial Supervisory Authority (Finanssivalvonta).
- This presentation may include forward-looking statements, estimates, and calculations related e.g. to the Company and its markets. Such forward-looking statements, estimates, and calculations are based on expectations and assumptions of the Company, which may be inaccurate or untrue. They also involve known and unknown risks and other factors, which might cause any estimates made by the Company to materially deviate from those actualized, including the operations, financial situation, and achievements of the Company. The Company cannot be held liable for any such deviations or for any actions taken by any party based on this presentation. Known risks related to the future of the Company and its business have been described in the formal prospectus approved by Finland's Financial Supervisory Authority (Finanssivalvonta).




Where do pharmaceuticals come from?






Novel drugs are based on science

- Scientific discovery on disease mechanisms; or
- Novel molecule, which may be clinically relevant



Herantis' drug development strategy



Herantis Pharma på svenska



- Herantis Pharma är ett innovativt läkemedelsutvecklingsbolag med inriktning mot regenerativ medicin med två proprietära läkemedel i kliniska tester:
 - → CDNF mot Parkinsons sjukdom: ämnar att stoppa sjukdomens utveckling
 - → Lymfactin® mot sekundär lymfödem: världens första och enda genterapi i klinisk testfas (fas II) som **reparerar skador på lymfsystemet**
- Båda är baserade på världsledande medicinsk forskning
- Herantis Pharmas aktie är noterad på Nasdaq First North Helsingfors

→ Vi planerar att notera vår aktie på **First North Stockholm** under 2019



Neuroprotective factor CDNF

for stopping the progression of Parkinson's disease






© 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

Parkinson's disease (PD)


- Progressive neurodegenerative disease impacting 7-10 million people
- Estimated annual financial burden of PD is \$50 billion
- L-dopa, a standard-of-care, has been used since 1960's!
- Known therapies only alleviate motor symptoms; Herantis' CDNF aims to also stop disease progression







CDNF's natural role is to help neurons survive

- CDNF helps stressed or injured neurons survive and recover
- Mechanisms relevant to PD
- Promising data in several neurological diseases



CDNF doubled the number of neurons in a PD model*





- Disease model: Severe parkinsonism in aged Rhesus monkey
- Three monthly CDNF doses **doubled the number of neurons**
- Significant improvement in gross motor function, fine motor function, and for the first time in the world, also in non-motor symptoms



* Research collaboration with University of Pittsburgh funded by Michael J. Fox Foundation

CDNF may change how patients live with PD

Currently in Phase 1-2 clinical study funded by European Union:
"Leading science, greatest potential to advance clinical practice"




Study fully recruited: 17 patients randomized in CDNF vs. placebo groups

- Topline results expected by end of 2019
- > First-in-human study in late-stage PD patients \rightarrow Primary endpoint is safety



Next generation: xCDNF

 Common challenge in brain diseases is drug delivery in the brains → CDNF is dosed with sophisticated medical device



- We have shown that certain fragments of CDNF:
 - 1. Retain its biological activity (comparable efficacy in PD models)
 - Reach the brain with systemic dosing → much simpler administration
 - 3. Have potential in several indications beyond PD: E.g. Alzheimer's, ALS, stroke

Based on current data xCDNF could be administered as easily as insulin



Lymfactin® gene therapy for curing secondary lymphedema



Secondary lymphedema


- Lymphedema (LE) is chronic, progressive swelling due to accumulation of lymph
 - \rightarrow Disabling and disfiguring disease
 - \rightarrow No approved drugs for treatment
- Herantis' Lymfactin® is a gene therapy that aims to repair the lymphatic system





Lymfactin® aims at reconstituting the lymphatic system


- A single Lymfactin® injection results in local VEGF-C expression for about 2 weeks
- 2. VEGF-C is the natural human protein that promotes the growth of lymphatic vessels
- 3. Functional lymphatic system is reconstituted





Lymfactin® is in Phase 2 clinical studies

- Actively recruiting patients with breast cancer associated LE who are undergoing lymph node transplantation as an attempt to relieve symptoms
- Study centers: 5 university hospitals in Sweden and Finland
- Target: 40 patients randomized in Lymfactin® vs. placebo groups
- Topline results expected by end of 2020 (12-month follow-up)
- Primary endpoints: Efficacy in signs and symptoms of LE






Summary

HERANTIS

© 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

CDNF and Lymfactin® are in placebo-controlled studies that target significant unmet needs




* Randomized, double-blind, placebo-controlled Phase 2 clinical study ** Randomized, double-blind, placebo-controlled Phase 1/2 clinical study



Herantis Pharma

- Targeting disease modification in significant unmet medical needs, large and well-defined markets
- Programs based on internationally renowned science published in Nature and Science
- Funded to **reach unblinding** in two randomized clinical studies
- Considering possible dual listing in First North Sweden in 2019





About Herantis' management and shareholders

- International and experienced Board of Directors
- Herantis' management has actively purchased shares both from the market and participated in share issues
- All insider trading published on the company's website
- Cornerstone investor in last funding round (3/2019) was Swedbank Robur's fund, Medica



HERANTIS PHARMA



Thank you

E-mail: pekka.simula@herantis.com Twitter: @HerantisPharma Blog: http://herantis.com/blog/

21

© 2014-2019 HERANTIS PHARMA Plc. All rights reserved.